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Abstract
Background: In Nigeria, urbanisation and increasing life expectancy are likely to increase the incidence of
non-communicable diseases. As the epidemic of diabetes matures, visual loss from diabetic retinopathy (DR) will
increase unless mechanisms for early detection and treatment improve, and health systems respond to the growing
burden of non-communicable diseases.
Methods: A nationally-representative population-based sample of 13,591 participants aged ≥40 years selected by
multistage-stratified-cluster-random-sampling with probability-proportional-to-size procedures were examined in
305 clusters in Nigeria between January 2005 to June 2007. All were asked about history of diabetes and underwent
basic eye examination. Visual acuity (VA) was measured using logMAR E-chart. Participants with VA<6/12 and/or DR
detected underwent detailed eye examination including dilated retinal examination and retinal photography.
Systematic sampling of 1-in-7 gave a subsample (n=1759) examined in detail regardless of VA; and had random blood
glucose (RBG) testing. Images were graded by Moorfields Eye Hospital Reading Centre. Participants were defined as
having diabetes if they were previously diagnosed or RBG>11.1mmol/l or had DR. Data in the subsample were used to
estimate the prevalence and to analyse risk factors for diabetes and DR using multivariable logistic regression.
Additional information on the types of DR was obtained from participants not in the subsample.
Results: In the subsample, 164 participants were excluded due to missing data; and 1,595 analysed. 52/1,595 had
diabetes, a prevalence of 3.3% (95%CI 2.5-4.3%); and 25/52(48%) did not know. Media opacity in 8/52 precluded retinal
examination. 9/44(20.5%) had DR. Higher prevalence of diabetes was associated with urban residence (Odds ratio [OR]
1.87) and overweight/obesity (OR3.02/4.43 respectively). Although not statistically significant, DR was associated with
hypertension (OR3.49) and RBG>15.0mmol/L (OR8.10). Persons with diabetes had 3 times greater odds of blindness. Of
11,832 other participants in the study sample, 175(1.5%) had history of diabetes; 28 had DR. Types of DR (total=37)
included 10.8% proliferative, 51.4% macular oedema.
Conclusion: The age-adjusted prevalence of diabetes in Nigeria was 3.25% (95%CI 2.50-4.30) and over 10% of people
with diabetes aged ≥40 years had sight-threatening-DR. These data will enable the development of better public
health strategies for the control of diabetes and planning services for DR to prevent vision loss.
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Background
The number of people (aged 20-79 years) with diabetes
mellitus (diabetes) worldwide is projected to increase from
382 million in 2013 to 592 million in 2035 [1]. India and
other parts of Asia will have the highest number of people
with diabetes by 2035, but the highest percentage increase
will be in the Middle Eastern Crescent (+96%) and Sub-
Saharan Africa (+109%) [1]. In Sub-Saharan Africa the
number of people with diabetes is projected to increase
from 19.8 million in 2013 to 41.4 million in 2035 [1] but
public health strategies for managing the emerging dia-
betes epidemic are inadequate or non-existent.
Globally, diabetic retinopathy (DR) accounts for 5% of
all blindness, affecting 2 million people [2], and it is the
leading cause of blindness in people aged 15 – 64 years
in industrialized countries. Diabetic retinopathy can be
classified into two broad categories: non-proliferative DR
(NPDR) and proliferative DR (PDR). PDR and diabetic
macular edema (DME) are both sight-threatening and
can result in visual impairment and/or blindness. The
major risk factors for DR are long duration of diabetes,
poor glycaemic control and hypertension [3], and there
is evidence from clinical trials that early treatment of
PDR and DME can preserve visual acuity [4]. Visual loss
from DR is, therefore, potentially avoidable. Indeed, it
has been estimated that blindness from DR could be re-
duced by as much as 90% if agreed treatment protocols
and standardized care for diabetics were to be imple-
mented [2].
In Nigeria, a national survey of non-communicable
diseases undertaken in 1992 reported the national preva-
lence of diabetes to be 2.8% (95% CI 2.6-3.1%) in per-
sons aged 15 years and above [5]. In another survey in
an urban population in southern Nigeria the prevalence
of diabetes was 6.8% (95% CI 4.6-9.0%) among those
aged 40 years and above [6], while other studies reported
prevalence figures ranging from 1.6% to 12.7% in those
aged 15 years and above [7-12]. In Ghana the adjusted
prevalence of diabetes was 6.4% (95% CIs not reported)
among those aged 25-years and above [13]. However,
none of the studies in West Africa reported the propor-
tion of persons with diabetes who had DR.
In Nigeria there is rapid urbanisation and increasing life
expectancy, so an increase in the incidence of non-
communicable diseases (NCD), including diabetes, is to
be anticipated. Indeed, data from the Nigeria national
blindness and visual impairment survey showed that the
prevalence of hypertension is already very high (44.9%;
95% CI 43.5-46.3%) [14].
Nigeria has the largest population of all African coun-
tries, being 128 million at the time of the national blind-
ness and visual impairment survey (January 2005 to June
2007). Nigeria has six main administrative divisions/geo-
political zones (GPZ), 36 states and a Federal Capital
Territory; 50.3% of the population live in urban areas, and
62.6% live below the poverty line [15] despite a rapidly
increasing GDP.
This paper reports findings in relation to diabetes
and DR from the Nigeria national blindness and visual
impairment survey, which involved participants aged
40 years and above across the country between 2005
and 2007. The following are presented in this paper:
the prevalence of diabetes and risk factors for diabetes;
the prevalence and types of DR and risk factors for DR,
and the causes of vision loss in participants with diabetes.
The national survey gave a prevalence estimate for blind-
ness (presenting visual acuity [VA] of <3/60 in the better
eye) of 4.2% (95% CI 3.8-4.6%) [16]. Cataract was the com-
monest cause of blindness (43%) and DR was responsible
for 0.5% of blindness [17]. More in-depth data on diabetes
and DR will enable the development of better public
health strategies for the control of diabetes, and planning
services for DR to prevent vision loss.
Methods
Study design and clinical assessment
The Nigeria national blindness and visual impairment
survey was a cross-sectional population-based survey
designed to determine the prevalence and causes of blind-
ness and visual impairment. Multistage stratified cluster
random sampling with probability-proportional-to-size
procedures were used to ensure a nationally representative
sample, and 13,591 of the 15,027 enumerated individuals
aged 40 years and above were examined (response rate
90%) in 305 clusters across the 36 states and Federal
Capital Territory of Nigeria (Figure 1). Survey methods
have been described in detail, including, quality assurance
and data management [18]. Data were collected by two
teams of Nigerians each comprising two ophthalmologists,
one optometrist and two ophthalmic nurses. Inter-
observer agreement studies of visual acuity (VA) testing
were performed during pilot studies undertaken in each of
the six geopolitical zones (GPZ), which are the main ad-
ministrative divisions in the country. The average kappa
statistic for VA testing were 0.53 (moderate agreement)
for inter-observer differences of one or less letters; and
0.39 (fair agreement) for inter-observer differences of two
or less letters. For Mehra-Minassian lens opacity grading
[19] the kappa was 0.70 (substantial agreement).
The study adhered to the tenets of the Declaration of
Helsinki and ethical approval was obtained from the Ethics
Committee of the London School of Hygiene & Tropical
Medicine and the Federal Ministry of Health, Nigeria. In-
formed verbal consent was obtained from community
leaders, heads of households and all participants. All partici-
pants identified with ocular pathology requiring assessment
and/or treatment were referred to the nearest eye service,
including those with sight threatening DR (STDR).
Kyari et al. BMC Public Health 2014, 14:1299 Page 2 of 12
http://www.biomedcentral.com/1471-2458/14/1299
Selection of the subsample
Systematic sampling of 1-in-7 of all participants (N =
13,591) at the time of registration gave a subsample
(n = 1,759) (Figure 2), who were all examined in detail (see
below) regardless of presenting VA or ocular findings.
Participants in the subsample had random blood glucose
(RBG) testing of capillary blood drawn with a lancet finger-
prick (Omron one-touch ultra blood glucose meter). This
subsample was used to estimate the prevalence of diabetes
and DR, and to assess their risk factors.
Procedures on all participants
All participants were interviewed to obtain information
on personal and demographic details and they were asked
whether they had diabetes previously diagnosed by a doc-
tor or were on treatment for diabetes. Height was mea-
sured to the nearest tenth of a centimeter and weight to
the nearest 100gram using standard equipment. Blood
pressure (BP) was recorded three times with BP Omron
wrist instrument (Omron Healthcare Ltd, Milton Keynes,
England) after resting for at least 10 minutes. Average
values were used in this analysis. Presenting and best cor-
rected VA were measured using a reduced logMAR
tumbling-E chart. [20,21] All participants had a basic eye
examination by an ophthalmologist.
Detailed eye examination
All participants in the subsample as well as participants
with a VA <6/12 in one or both eyes and/or DR or other
posterior ocular pathology seen on undilated fundos-
copy also underwent detailed eye examination. Detailed
examination was performed by experienced ophthal-
mologists and included slit-lamp biomicroscopy (Zeiss
SL 115 Classic Slit Lamp, Carl Zeiss Meditec AG Jena
Germany) and dilated retinal examination using 60D
aspheric condensing lens (Volk) and binocular indirect
ophthalmoscopy (BIO; Keeler all-pupil) with a 20D lens.
Lens opacities were graded using the Mehra-Minassian
[19] and World Health Organization (WHO) grading
systems [22]. Participants also had digital retinal pho-
tography (Zeiss Visucam Lite Desk Top Fundus Camera,
Carl Zeiss Meditec AG Jena Germany) focused on the
optic nerve head and the macular region through a dilated
pupil. Images were graded by Moorfields Eye Hospital
Reading Centre (MEHRC).
Data on the types of diabetic retinopathy
Data on the types of DR were obtained from two
sources. First, from diabetics identified in the subsample
and second from the larger number of participants not
in the subsample (n = 11,832) (Figure 2) in whom DR
was detected.
Definition of diabetes, diabetic retinopathy and vision loss
Diabetes was defined as a self-reported positive history of
diabetes, or a RBG of 11.1 mmol/l or higher [23] (sub-
sample only) and/or DR was detected on dilated retinal
examination and/or was identified by MEHRC from im-
ages. Among those with a history of diabetes, the duration
of diabetes was not ascertained as this was likely to be very
unreliable and it was anticipated that a high proportion of
diabetics would not have been diagnosed. In the MEHRC,
Figure 1 Map of Nigeria showing cluster sites and magnitude of blindness for the Nigeria National Blindness and Visual Impairment
Survey.
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images were viewed “full screen” on a 24-inch Eizo
S2433W monitor calibrated using a DataColor Spyder 2
calibrator or a 24-inch widescreen Dell 2407wfp monitor
calibrated using a Gretag Macbeth Eye One Display 2 cali-
brator. Diabetic retinopathy was defined as the presence
of microaneurysms, dot-blot haemorrhages, intra-retinal
microvascular anomalies (IRMA), new vessels on the disc
or elsewhere, cotton-wool spots, exudates and clinically
significant macular edema. Diabetic retinopathy was clas-
sified as NPDR, PDR and DME based on a modified
ETDRS classification [24]. If retinal images were not avail-
able nor readable due to media opacity, findings recorded
by the examining ophthalmologists were used.
Visual acuity was classified using WHO categories which
use the presenting VA in the better eye. Moderate visual
impairment (VI) was defined as <6/18 to >6/60; severe VI
as <6/60 to >3/60, and blindness as <3/60 [25]. An add-
itional category of mild VI was included i.e. <6/12 to >6/18.
All participants with a presenting VA of <6/12 in one or
both eyes were examined in detail, and all possible causes
of vision loss were listed for each eye. The most preventable
or treatable disorder was then selected as the main cause
for the person, using WHO guidelines [26].
Data analysis and statistical methods
a) Subsample (n = 1,759)
Participants with a positive history of diabetes were
classified as known diabetics, those with a raised RBG
who were unaware they had diabetes were classified as
new diabetics, and those with missing data on their
diabetes status were excluded. This dataset was used to
estimate the prevalence of diabetes and DR, and for
analyses of their risk factors (n = 1,595).
The risk of diabetes and DR were assessed in relation
to socio-demographic factors (increasing age, gender,
ethnicity and literacy); location (urban residence and
GPZ) and biophysical factors (hypertension and body
mass index). Risk factors for DR also included axial
length. The association of diabetes with vision loss
was also assessed. Age was grouped in 10-year
categories; ethnic groups with >100 participants
Known 27
New 25
Total 52
Types of diabetic retinopathy 
n=37
Prevalence and risk 
factors for diabetes
Prevalence and risk 
factors for diabetic 
retinopathy
Diabetic retinopathy n=28Diabetic retinopathy n=9/44
No view of retina n=8
Detailed eye examination, 
with digital imaging
Detailed eye examination, 
with digital imaging
Excluded n=164
No data on diabetes 
n=1759
1 in 7 subsample Eligible for detailed eye 
examination n=4638
Not eligible for detailed 
eye examination n=7194
Examined
n=13,591
History of diabetes; height, 
weight, blood pressure
Random blood glucose
Diabetics
Enumerated
15,027
Basic eye examination
Figure 2 Flow chart showing how different denominators were derived for analyses of diabetes and diabetic retinopathy.
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(Fulani, Hausa, Ibo and Yoruba) were analysed
separately, combining smaller ethnic groups into an
“others” category. Literacy was defined by the ability
to read and write and urban residence was defined as
a settlement of more than 20,000 people. Hyperten-
sion was defined as WHO stage 1 for systolic/diastolic
BP of >140/90 mmHg, stage 2 > 160/100 mmHg and
stage 3 > 180/110 mmHg [27]. Body mass index (BMI)
was calculated by dividing body weight (kg) by height
(m) squared and categorized according to the WHO
international classification for adults i.e., underweight
(<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight
(25.0–29.9 kg/m2) and obese (>30.0 kg/m2) [28].
Random blood glucose was grouped as normal
(<11.1 mmol/L), high RBG > 11.1-14.9 mmol/L and
high RBG > 15.0 mmol/L. Axial length was assessed as
a continuous variable and as quartiles.
Associations with potential risk factors were explored
using the Pearson design-based F test for binary traits
and other categorical data. Univariate and multivariate
logistic regression analyses were performed to identify
significant associations. Risk factors identified in univar-
iate analyses with p-values <0.2 were included in the
multivariate analyses. Adjusted odds ratios (OR) with
95% confidence intervals (CI) were calculated. All ana-
lyses took account of additional variation introduced by
the stratified cluster sampling design. P-values <0.05
were considered as statistically significant.
b) Whole dataset
The number of participants with DR among those not in
the subsample (n = 11,832) was also determined. The
types of DR and the main cause of vision loss seen in all
persons with DR in the whole dataset were also described.
Missing values were excluded from all analyses. All the
analyses were performed using Stata (Stata/IC 13.1;
Stata Corp, College Station, TX).
Results
The subsample was representative of the whole study sam-
ple by age, gender and place of residence (Table 1). The
mean age (standard deviation [SD]) for the whole sample
was 55.9 (12.4) years and for the 1-in-7 subsample was
56.1 (12.1) years. The difference in the means was not sta-
tistically significant (p = 0.62). In the subsample, 164 par-
ticipants had insufficient data to determine their diabetes
status and were excluded from the diabetes analysis. The
excluded participants did not differ to those analysed with
respect to age (p = 0.09), gender (p = 0.74) and place of
residence (p = 0.70). The mean age (SD) for those analysed
in the subsample was 56.1 (12.0) years and for those ex-
cluded in subsample because of missing data was 55.4
(13.3) years. The difference in the means was not statisti-
cally significant (p = 0.48).
Prevalence of diabetes and risk factors associated with
diabetes
In the subsample, 164 (9.3%) participants had missing data
on diabetes status and so were excluded, leaving 1,595 for
analysis. The prevalence of diabetes was 3.3% (95% CI 2.5 -
4.3%). Of the 52 participants who had diabetes, 25 (48%)
were not aware that they had diabetes (new); and over half
of the 27 who knew they had diabetes (52%) had high
RBG > 11.1 mmol/L. Although the differences were not
statistically significant, those who did not know they had
diabetes were more likely to be younger than 50 years or
older than 70 years, female and living in rural areas.
The prevalence of diabetes was highest in those aged
80 years and above (8.1% 95% CI 3.7-16.9), being 2.9%
(95% CI 2.0-4.1%) among those aged 40-59 years, the eco-
nomically active age group. There were no differences by
gender or ethnic group (Table 2). The age-specific diabetes
prevalence standardized to the 2012 population of Nigeria
also showed increasing diabetes prevalence with increas-
ing age above 40 years (Table 3). People with diabetes
were more likely to live in urban areas, to be overweight
or obese, literate, hypertensive (any stage) and blind
(Table 4). In multivariate analysis, being aged 80 years and
above, living in an urban location, and being overweight
or obese remained independent risk factors.
Prevalence of diabetic retinopathy and risk factors
associated with diabetic retinopathy
In eight individuals the posterior pole could not be exam-
ined due to cataracts, corneal opacity or vitreous opacity
(Table 5). The proportion of persons with diabetes with
Table 1 Socio-demographic characteristics of the
subsample compared with the whole study population
Whole study population
N = 13591
1-in-7 subsample
n = 1759
N % (95% CI) n % (95% CI)
Socio-demographic factors
Age-group in years (p = 0.62)
40-49 4889 36.0 (34.8-37.2) 616 35.0 (32.7-37.4)
50-59 3577 26.3 (25.5-27.2) 461 26.2 (24.1-28.4)
60-69 2773 20.4 (19.6-21.2) 368 20.9 (19.1-22.8)
70-79 1653 12.2 (11.5-12.9) 229 13.0 (11.5-14.7)
80+ 699 5.1 (4.7-5.7) 85 4.9 (4.0-5.9)
Gender (p = 0.44)
Female 7345 54.0 (53.1-55.0) 937 53.3 (51.0-55.5)
Male 6246 46.0 (45.0-46.9) 822 46.7 (44.5-46.8)
Place of residence (p = 0.13)
Rural 10540 77.6 (72.5-81.9) 1371 77.9 (72.9-82.3)
Urban 3051 22.4 (18.1-27.6) 388 22.1 (17.7-27.1)
Total 13591 100 1759 100
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data on retinal findings who had any type of DR was
20.5% (9/44). Persons who knew they had diabetes had a
higher rate of DR than persons newly diagnosed with dia-
betes: 25.0% (6/24) compared with 15.0% (3/20) respect-
ively. Two thirds of the DR was sight-threatening, which
affected 1 in 7 of persons with diabetes.
Other retinal and/or macular pathology was detected in 12
(23.1%) of participants in the subsample with diabetes but
who did not have DR (e.g. branch retinal vein occlusion).
Risk factors for DR among people with diabetes in the
subsample
In univariate analysis, the only factors associated with DR
at the p ≤ 0.2 level were hypertension (any, and stages 2
and 3) and high RBG > 15.0 mmol/L (OR 9.0; 95% CI
0.89-91.43, p = 0.06). In multivariable analysis, high RBG
> 15.0 mmol/L was the strongest predictor of DR but it
did not reach statistical significance (OR 8.1; 95% CI 0.81-
Table 2 Prevalence of diabetes, by socio-demographic
and biophysical factors, in the subsample
Total Diabetes Prevalence
N n % 95% CI P
value
Socio-demographic
factors
Age group
(years)
40 - 49 557 14 2.5 1.5-4.2 0.17
50 - 59 412 14 3.4 2.0-5.6
60 - 69 346 11 3.2 1.7-5.9
70 - 79 206 7 3.4 1.6-6.9
80+ 74 6 8.1 3.7-16.9
1595
Gender Female 852 23 2.7 1.8-4.0 0.19
Male 743 29 3.9 2.7-5.7
1595
Ethnic
group
Fulani 83 2 2.4 0.6-8.9 0.87
Hausa 384 11 2.9 1.6-5.0
Ibo 224 7 3.1 1.4-7.0
Yoruba 335 14 4.2 2.5-6.9
Others 562 18 3.2 2.0-5.1
1588*
Literacy Illiterate 894 21 2.4 1.5-3.6 0.02
Literate 701 31 4.4 3.1-4.3
1595
Location:
residence
Rural 1240 31 2.5 1.8-3.5 0.001
Urban 355 21 5.9 3.9-8.9
Location:
geopolitical
zone
South East 192 5 2.6 1.0-7.0 0.90
North West 432 12 2.8 1.7-4.7
North Central 267 8 3 1.4-6.2
South South 230 8 3.5 1.7-7.1
South West 343 13 3.8 2.3-6.2
North East 131 6 4.6 2.1-9.7
Biophysical
factors
Blood
pressure
(mmHg)
Normal 878 21 2.4 1.6-3.7 0.03
Hypertension
(any)
710 31 4.4 3.1-6.1
1588*
Blood
pressure
(mmHg)
Normal 878 21 2.4 1.6-3.7 0.13
Hypertension
stage 1
373 15 4 2.5-6.5
Table 2 Prevalence of diabetes, by socio-demographic
and biophysical factors, in the subsample (Continued)
Hypertension
stage 2
189 8 4.2 2.2-8.1
Hypertension
stage 3
148 8 5.4 2.8-10.3
1588*
Body mass
index
(kg/m2)
Underweight 187 3 1.6 0.5-4.9 <0.001
Normal 968 20 2.1 1.3-3.2
Overweight 286 17 5.9 3.8-9.3
Obese 134 11 8.2 4.7-14.0
1575*
Visual
acuity
Not blind
(>3/60)
1542 46 3 2.3-4.0 0.001
Blind (<3/60) 53 6 11.3 5.1-23.2
Total 1595 52 3.3 2.5-4.3
*missing values excluded.
Table 3 Age-standardized diabetes prevalence
Sub-sample Prevalence of diabetes
Crude rate Age-adjusted rateα
N % n % % 95% CI
Age group (years)
40-49 557 34.9 14 2.51 1.93 1.95-5.46
50-59 412 25.8 14 3.40 3.39 2.01-5.62
60-69 346 21.7 11 3.18 4.66 1.16-4.03
70-79 206 12.9 7 3.40 5.63 0.97-4.17
80+ 74 4.6 6 8.11 6.17 4.86-22.22
Total 1595 100.0 52 3.26 3.25 2.50-4.30
α = standardised to Nigeria 2012 population.
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81.20). Confidence intervals were wide around all odds ra-
tios due to the small sample size (data not shown).
Visual impairment/blindness in diabetes and diabetic
retinopathy
In the subsample 15/52 (28.8%) of those with diabetes
were visually impaired. Uncorrected refractive error was
the commonest cause (40%), followed by cataract and
uncorrected aphakia (20% and 6% respectively). Other
causes included optic atrophy, age related macular de-
generation, corneal opacity and unexplained. People with
diabetes were over three times more likely to be blind
than those without diabetes (adjusted odds ratio 3.2,
95% CI 1.2-9.3) (Table 3).
Table 4 Univariate and multivariable analysis of risk factors for diabetes
Univariate analysis Multivariate analysis
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Socio-demographic factors
Age group (years) 40 - 49 Reference Reference
50 - 59 1.36 0.64-2.91 0.43 1.33 0.62-2.87 0.47
60 – 69 1.27 0.55-2.96 0.58 1.59 0.67-3.76 0.29
70 – 79 1.36 0.55-3.38 0.50 1.60 0.59-4.40 0.36
80+ 3.42 1.32-8.81 0.01 5.04 1.80-14.11 0.00
Gender Female Reference Reference
Male 1.46 0.83-2.59 0.19 1.52 0.79-2.95 0.21
Ethnic group Fulani Reference - - -
Hausa 1.19 0.27-5.26 0.81
Ibo 1.31 0.26-6.54 0.74
Yoruba 1.77 0.41-7.69 0.45
Others 1.34 0.31-5.77 0.69
Literacy Illiterate Reference Reference
Literate 1.92 1.09-3.40 0.02 1.93 0.92-4.06 0.08
Location: Rural Reference Reference
Place of residence Urban 2.45 1.39-4.32 0.00 1.87 1.01-3.47 0.05
Location: South east Reference - - -
Geopolitical zone North west 1.07 0.34-3.41 0.91
North central 1.16 0.32-4.14 0.82
South south 1.35 0.38-4.82 0.65
South west 1.47 0.47-4.64 0.51
North east 1.80 0.49-6.63 0.38
Biophysical factors
Blood pressure Normal Reference - - -
Hypertension (any) 1.86 1.06-3.29 0.03
Blood pressure Normal Reference Reference
Hypertension stage 1 1.71 0.88-3.31 0.11 1.37 0.70-2.70 0.36
Hypertension stage 2 1.80 0.79-4.13 0.16 1.18 0.47-3.00 0.73
Hypertension stage 3 2.33 1.00-5.44 0.05 1.38 0.53-3.62 0.51
Body mass index Underweight 0.77 0.22-2.66 0.69 Reference 0.30-2.56 0.60
Normal Reference 1.00
Overweight 3.00 1.53-5.87 0.01 3.02 1.43-6.39 0.00
Obese 4.24 2.02-8.89 0.00 4.43 1.82-10.78 0.00
Visual acuity Not blind (VA >3/60) Reference Reference
Blind (VA <3/60) 4.15 1.69-10.22 0.00 3.20 1.10-9.30 0.03
VA = visual acuity.
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Types of diabetic retinopathy
In the subsample, six of the nine individuals with DR
had STDR (one with PDR; five with DME). Among the
11,832 individuals not in the subsample 175 had a his-
tory of diabetes and 28 participants were identified with
DR. Over half of the individuals with DR (16/28, 57.1%)
did not know they had diabetes.
The types of retinopathy in the most affected eye in the
37 participants with DR (i.e. 9 in the subsample; 28 not in
the subsample) were as follows: NPDR 27 (72.9%); PDR 4
(10.8%) and DME 19 (51.4%). Thus, STDR requiring as-
sessment for treatment was identified in 23/37 (62.2%)
participants with DR. Among the 37 participants with DR,
3 (8%) were blind, 27 (73.0%) had VI and 7 (19.0%) had
normal vision. The commonest cause of VI was uncor-
rected refractive error; and DR was the cause of vision loss
in two of the three blind individuals and in 4/27 with VI.
All three who were blind knew they had diabetes and had
advanced diabetic eye disease. One was a 42 year old man
with a RBG >33.3 mmol/L. He had bilateral aphakia, optic
atrophy and PDR with vitreous traction.
Discussion
This study provides new and nationally representative data
on the prevalence of diabetes mellitus and DR in Nigeria
as well as socio-demographic and biophysical risk factors.
Population-based nationally representative data are not
available for most developing countries, particularly in
Africa. An earlier Nigerian study reported the adjusted na-
tional standardised prevalence of diabetes to be 2.2% in all
ages, which varied from 0.6% in a rural community to 7%
in the urban population of Lagos, the former capital city
[5]. Other studies in Nigeria involved small sample sizes
in highly selected communities [8,11,29,30] or urban pop-
ulations (Port Harcourt [6] and Lagos [9]). The prevalence
of diabetes reported in our study was not as high as that
in Latinos (22.9%) [31], Saudi Arabia (29.7%; 95% CI 28.1-
31.4%) [32] Mexico (21%, 95% CI 19.5-23.1%) [33], or in
Asia (3.7% to 35%) [34-40] where a prevalence as high as
33.6% (95% CI 31.4-35.8) was reported in Singaporean
Indians [38] and 35% (95% CI not reported) in the urban
middle class population of Bangladesh [40]. The lower
prevalence in Nigeria may reflect high levels of poverty
and less exposure to known risk factors, shorter life ex-
pectancy, and importantly, poor control and high mortal-
ity among people with diabetes.
Many surveys report that a very high proportion of
people with diabetes are unaware that they have the condi-
tion with most reporting that for every known person with
diabetes there is at least one who is not diagnosed [6,13,41].
In our study, persons aged <50 or >70 years, females and
those living in rural areas were more likely to have undiag-
nosed diabetes, indicating that these groups may be target
groups for health education and diabetes testing.
As in our study, urban populations were at a greater
risk of diabetes [5,6], having two-fold greater risk [42]. It
is postulated that urbanization is associated with chan-
ging lifestyles which lead to a high-calorie diet and obes-
ity, and less physical activity. In Nigeria, women with a
higher BMI have higher RBG levels [43] and type II dia-
betes [6] and our study also shows that being over-
weight/obese is an important risk factor for diabetes.
Obesity is culturally acceptable and even desirable in
many parts of Nigeria, and often seen as a marker of
wealth and high standard of living. The same applies to
having a car and not walking anywhere, or not working
on the land or at home. Thus, behaviour and dietary
change interventions may be very challenging and an
area for further research in Nigeria.
The prevalence of hypertension, a major risk factor for
diabetic retinopathy, is also high in Nigeria [14], being
higher among those with diabetes.
The proportion of persons with diabetes who have DR
varies in different populations, being high among adults
Table 5 Retinal/macular findings in the most affected eye of participants with diabetes in the subsample
Known DM (n = 27) New DM (n = 25) Total (n = 52)
N % N % N %
Unable to assess fundus (poor view) 3 5 8#
Data on retinal findings 24 100% 20 100% 44 100%
Normal retina and macula 12 11 23
Diabetic retinopathy: 6 25% 3 15% 9 20.5%
Non-proliferative 2 1 3 3
Proliferative 1 0 1 1*
Diabetic macular edema 3 2 5 5@
Other retinal/macular abnormality 6 25% 6 30% 12 27.3%
DM = diabetes mellitus; NPDR = non-proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; DME = diabetic macular edema.
*NPDR in the other eye.
@3 had DME and NPDR in the same eye.
#Unable to view fundus in both eyes, or of other eye if one eye was normal: cataract (5), corneal opacity (1), vitreous haze (2).
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in Mauritius (33%) [44], those aged 40 years and above
in Latinos in Los Angeles, United States (47%) [31],
Singaporean Malays (35%) [35], Singaporean Indians
(30%) [38], the Handan Chinese (45%) [37] and in the
those aged 50 years and above in Saudi Arabia (37%)
[32] and Mexico (39%) [33]. However, reported rates
were generally lower in studies undertaken in middle in-
come countries , being similar to our study: i.e. 19% in
Andra Pradesh, India [34], 18% in Chennai, India [36],
15% in Guangzhou, China [45] and 7.6% in Sao Paulo
State, Brazil [46]. Reasons for the lower proportion of
DR among persons with diabetes in Nigeria compared
with high income settings are likely to reflect a combin-
ation of factors. Firstly, the onset of the epidemic of
diabetes is recent and most people with diabetes would
not have had the condition long enough to develop DR.
Second, many of participants with diabetes had signifi-
cant un-operated cataract which would underestimate
DR. Third, poor control of diabetes, as demonstrated in
our study, is likely to increase the risk of other compli-
cations such as cardiovascular disease, renal failure and
infection [47,48] and so increase the mortality rate. In
our study, the proportion of DR that was sight threat-
ening was high, possibly due to the high rates of uncon-
trolled diabetes and hypertension, but the sample size
was small. Also, data on types of DR was derived from
the whole study sample so the 28 cases of DR diagnosed
in the non-normative sample would mainly have been de-
tected as they had vision loss. In settings with highly effi-
cient health systems and an educated population, rates of
DR among people with diabetes can be very low. For ex-
ample, in a study from Denmark only 7% of persons with
diabetes had DR [49] and none was sight-threatening.
Previous reports on DR in Nigeria were hospital-based,
and the findings are difficult to interpret due to variation
in case mix, methods of detecting DR and in the classifica-
tion systems used [50-59].
In our study, similar to reports from Los Angeles Latinos
[31], Mexico [33] and Brazil [46] persons with diabetes had
two-fold greater odds of being blind or visually impaired
than persons without diabetes, with the commonest causes
being cataract and uncorrected refractive error. In those
studies, DR was also a major cause of blindness in people
with diabetes [32,33,37]. However, in our study the contri-
bution of DR to vision loss will have been underesti-
mated, as the WHO method for assigning causes
requires examiners to preferentially select treatable or
preventable causes. For example, if an individual has
diabetic macular edema and significant cataract, cata-
ract should be selected as the cause as this is a readily
reversible cause of vision loss.
Strengths of this study are that it included a nationally
representative sample, and retinal images were read by
an internationally recognised reading centre. The survey
teams were highly experienced clinicians, and rigorous
quality control mechanisms were in place.
However, several limitations in relation to diabetes and
DR are acknowledged. First, for logistical reasons, RBG
testing was not feasible on the whole sample, but was only
performed on the subsample of participants. This meant
that the CIs around the prevalence estimate are wide
which limits the usefulness of estimates of magnitude.
Second, RBG was used rather than fasting blood glucose
as the latter was not feasible in the context of this very
large survey. To make a definite diagnosis of diabetes, re-
peat and confirmatory tests need to be done. Thirdly, the
diagnosis of diabetes was based on a RBG of >11.1 mmol/
L performed by a glucose meter. RBG testing is not a
widely accepted format for assessing prevalence of dia-
betes. It is a tool used mostly in clinical settings where
other options are limited. We acknowledge that the accur-
acy and reproducibility of this method is poor but the
results gave an estimate in a situation where there was
dearth of data for prevalence of diabetes. Furthermore, the
cut-off diagnostic value of >11.1 mmol/L would miss a
number of people with altered glucose intolerance and
diabetes. The aforementioned deficiencies could explain
the numbers of diabetes being lower than might have been
expected. The prevalence of diabetes presented here is
thus, a minimum estimate. Another limitation was that
diabetes was not classified as Type I or Type II, and infor-
mation on the duration of diabetes was not sought. Due
to lack of awareness of diabetes and inadequate primary
and secondary health services in Nigeria, people present
very late for a wide range of conditions, including diabetes.
The year of diagnosis of diabetes would, therefore, mark-
edly underestimate the duration of disease. The survey did
not include individuals aged under 40 years of age, and
diabetes may well be a problem in younger ages. Another
limitation was that not all participants had dilated fundos-
copy to detect DR and we might have missed some non-
proliferative DR by direct fundoscopy in persons with nor-
mal visual acuity who did not have dilated retinal examin-
ation. In relation to risk factors for DR among people with
diabetes, the power of the study to detect significant differ-
ences was low due to the small sample of participants with
DR, and metabolic risk factors such as HbA1c were not
assessed. Smoking was not explored as a risk factor, but
cigarette smoking is unusual in Nigeria [60] and question-
ing about this habit would not have been acceptable to
many participants. The limitations of this study underscore
the need to have further studies to provide precise esti-
mates on the prevalence of NCDs in Nigeria including dia-
betes mellitus and hypertension, in collaboration with
physicians and NCD experts using accurate and acceptable
guidelines for population-based diagnosis and surveys.
Diabetes and its complications are likely to have consid-
erable economic consequences both for individuals, their
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families and society. In Nigeria, health insurance is not yet
widely available, and government as well as private pro-
viders charge user fees for consultations. There are other
out of pocket expenditures for medication, blood tests and
other investigations, and for the management of complica-
tions. In our study one in every 35 adults of working age
(40-59 years) had diabetes, which is likely to impact on
economic productivity. Cost-effective and cost-saving in-
terventions are urgently needed for the early detection
and optimal management of diabetes in Nigeria [61] but it
is recognised that there are scarcity of resources and nu-
merous challenges to effective service delivery in Africa
[62]. Poor awareness of the disease underscores the need
for public health strategies for the diagnosis and treatment
of diabetes, especially in high-risk groups. There is also a
need for control of behavioural risk factors, such as diet
and exercise, to curtail the burden of NCDs in Nigeria,
through behaviour change interventions which are based
on sound evidence. Other challenges in relation to DR in-
clude lack of equipment for diagnosis and treatment, an
inadequately trained health workforce [62,63], poor drug
procurement and delivery mechanisms, low patient aware-
ness and adherence to treatment, poor attendance at eye
clinics despite referral and weak management information
systems [55]. Using projections from the 2013 Diabetes
Atlas, the number of people with diabetes in Nigeria is
likely to double over the next two decades. There is a need
for a national policy on screening for NCDs which is inte-
grated at the primary level of care and which addresses all
elements of the health system. Physicians involved in dia-
betic care, optometrists and other primary eye care
workers should ensure an effective system for detecting
DR among persons with diabetes with referral mecha-
nisms for confirmatory diagnosis and treatment. It has
been suggested that models of screening and treatment of
DR which are being implemented in India can be adapted
for sub-Saharan African countries [62]. Further research is
required to determine the optimum modes of service de-
livery to prevent, detect and treat DR and how eye health
systems can respond to the rapidly changing burden of
disease.
Conclusion
The study gives new epidemiological data for diabetes
and DR in Nigeria. It is estimated that about 10% of
people with diabetes aged ≥40 years in Nigeria may have
sight-threatening diabetic retinopathy. The data will be
relevant for development of health systems and services
to respond to the growing burden of diabetes and its
complications in sub-Saharan Africa.
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